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Abstract
Background: Nasal NK/T-cell lymphoma is a rare type of lymphoma in Caucasian individuals, but is relatively
common in Asian populations. Genetic variants in immune and inflammatory response genes may thus be associated
with the risk of developing lymphoma. Here, we investigated the association between immuno-modulatory gene
polymorphisms and risk for nasal NK/T-cell lymphoma in a Chinese population.
Methods: Analysis of 12 single nucleotide polymorphisms (SNPs) in IL-10, TNF-α, lymphotoxin-α (LTA), and CTLA-4
genes was performed for 125 patients with NK/T-cell lymphoma and 300 healthy controls by PCR-ligase detection
reactions.
Results: The LTA +252 GA + AA genotypes were associated with increased risk for NK/T-cell lymphoma (OR = 2.96,
95 % CI = 1.42–6.19, P = 0.004 for GA + AA genotype). Haplotype C-G-G-A (TNF-α -857, -308, −238 and LTA +252)
also conferred an increased risk (OR = 1.52, 95 % CI = 1.14–2.06, P = 0.005). Additionally, the LTA +252 GA + AA
genotype was associated with an even higher risk in populations positive for Epstein–Barr virus (OR = 5.20,
95 % CI = 1.22–23.41, P = 0.03 for the GA + AA genotype).
Conclusions: Our data suggest that the LTA +252 A > G polymorphism is associated with the risk of developing
NK/T-cell lymphoma, especially for Epstein–Barr virus-positive NK/T-cell lymphoma in the Chinese population.
Keywords: NK/T-cell lymphoma, Single nucleotide polymorphisms (SNP), Lymphotoxin-α
Background
NK/T-cell lymphoma is an aggressive type of cancer that
attacks natural killer (NK) and/or T-cells, which are key
immune cells that fight viruses, bacteria, and tumor cells.
This disease is also known as nasal NK lymphoma, angio-
centric lymphoma, or extranodal NK cell lymphoma.
Histological features of this lymphoma are vessel-centered
lesions, and extensive lymphoma infiltration of blood
vessels, which results in notable ischemic necrosis of
normal and neoplastic tissues [1, 2]. NK/T-cell lymphoma
is relatively uncommon and accounts for less than 1 %
of lymphomas in Europe and North America. However,
it is relatively common in Asia and Latin America, and
in China and Japan it constitutes 6–10 % of all lymph-
omas [1–3]. The etiology of NK/T-cell lymphoma is
complicated and poorly understood, but studies suggest
that Epstein–Barr virus (EBV), ethnicity, and geographic
factors contribute to the etiology of this disorder [2–4],
in addition to other factors that may be worthy of
exploration.
There is strong evidence that altered immunological
function entails an increased risk for lymphoma. Im-
mune and inflammatory response genes are the funda-
mental messengers of adaptive immunity, which regulate
the growth of lymphoid tissue and immune system
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function. Genetic polymorphisms of several immunity
genes were reported to be associated with non-Hodgkin
lymphoma (NHL) and its major subtypes [5–12]. For
this reason, investigation of immune related genetic
markers and NK/T-cell lymphoma is desirable.
Interleukin-10 (IL-10) and tumor necrosis factor
(TNF) are key cytokines that have been intensively in-
vestigated in autoimmune diseases and malignancies.
Both are important regulators for the Th1/Th2 balance,
apoptosis, and regulation of inflammation. IL-10 knock-
out mouse models showed that this cytokine affects
B-cell lymphomagenesis either indirectly or directly [13].
The TNF family consists of 19 members that mediate di-
verse biological functions in a variety of cellular systems,
and TNF-α and lymphotoxin-α (LTA, also named TNF-β)
are two important members of the TNF family. TNF-α
is produced primarily by activation of monocyte/macro-
phages and LTA by lymphocytes and NK cells. Even
though they are produced by different cells, their
biological effect is similar. In vitro studies show that
TNF-α or LTA play an important role in killing infected
or tumor cells by activated macrophages and cytotoxic
T cells [14]. However, the expression of endogenous
TNF resists the cytotoxicity of exogenous TNF to kill
tumor cells [14]. Notably, TNF may stimulate endogenous
tumor promoters. Thus, it is thought to be associated with
malignant tumors. A number of single nucleotide poly-
morphisms (SNPs) have been identified in these gene
regions. Among them, IL-10 -3575 A > T and TNF-α-
308 G > A SNPs were reported to be associated with NHL,
especially in diffuse large B-cell lymphoma (DLBCL) by
several different groups [9, 11, 12].
In addition to IL-10 and TNF, cytotoxic T lymphocyte
antigen 4 (CTLA-4), a member of the immunoglobulin
superfamily that is expressed mainly on activated T cells,
plays a critical role in the suppression of T-cell prolifera-
tion and activation. The inhibitory role of CTLA-4 in
maintaining homeostasis of inflammatory and immune re-
actions makes it a potential candidate gene for determining
the genetic predisposition of infectious and autoimmune
diseases. CTLA-4-deficient mice develop lymphoprolif-
erative disorders characterized by polyclonal T-cell pro-
liferation and early lethality [15]. Furthermore, CTLA-4
polymorphisms -318 C > T, +49 A > G, and CT60 A > G
are associated with susceptibility to autoimmune disorders
[16]. Recent reports also revealed that CTLA4 polymor-
phisms have a role in the occurrence of multiple myeloma
[17] and NHL [18].
Because NK/T-cell lymphoma is a rare subtype of NHL
worldwide, very little work has been done to understand its
pathogenesis, and, to the best of our knowledge, no study
has reported the genetic risk factors for this special type of
NHL. In this case-control study, we investigated the associ-
ation between several genetic variants of immunoregulatory
genes (IL-10, TNF/LTA, and CTLA-4) and risk for nasal
NK/T-cell lymphoma in a Chinese population.
Methods
Study subjects
This study included 125 cases that were newly diagnosed
as nasal type NK/T-cell lymphoma and recruited from the
following institutions: Shandong Cancer Hospital and
Institute, Shandong University Qilu Hospital, Shandong
Provincial Hospital, Jinan Fourth People's Hospital, and
the Affiliated Hospital of Taishan Medical University.
Subjects were recruited between January 2006 and
December 2011. All diagnosed patients met the World
Health Organization (WHO) Classification of Tumors
of the Hematopoietic and Lymphoid Tissues (2008)
diagnostic criteria. The pathological classification was
determined based on tissue sections with haematoxylin-
eosin staining and immunohistochemistry as well as
clinical characteristics. The immune phenotype markers
included CD2, CD3, CD56, CD45R0, TIA-1, granzyme
B, LCA, and EBV status. Over the same period, 300 con-
trols were accrued from healthy volunteers who visited
the general health check-up division or patients with
non-cancer diagnoses at Shandong Cancer Hospital
and Institute, Shandong University Qilu Hospital, and
Shandong Provincial Hospital. Controls did not have
malignancy or any autoimmune or immune-mediated
diseases. Randomly selected controls were matched to
the cases by age (±5 years) and gender. All subjects were
Han Chinese. At recruitment, informed consent was
obtained from each subject. This study was approved by
the Institutional Review Board of the Shandong Cancer
Hospital and Institute. Institutional Review Board ap-
proval has been obtained from all study sites.
All study participants provided 2 ml of peripheral
blood. Additionally, immunoglobulin-G antibodies to
EBV-VCA (R-Biopharm AG, Darmstadt, Germany) were
confirmed by serology testing using a standard enzyme-
linked immunosorbent assay for both case and control
subjects.
Genotyping
Gene names, chromosomal location, and the SNP data-
base IDs used for genotyping are listed in Table 1. Geno-
typing was carried out, blinded to case-control status, by
the Shanghai Biowing Applied Biotechnology Co., Ltd.
(Shanghai, China) using ligase detection reactions (LDR).
Target DNA sequences were amplified using a multiplex
PCR method and ligation reactions for each subject were
carried out in a final volume of 10 μL containing 1 μL of
10× buffer, 100 ng of multi-PCR product, 1 pmol of each
discriminating oligo, 1 pmol of each common probe, and
2 U of Taq DNA ligase (New England Biolabs, Beverly,
MA, USA). The LDR parameters were as follows: 94 °C
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for 2 min, 35 cycles at 94 °C for 30 s, and 50 °C for 2 min.
Following the LDR reaction, 1 μL of reaction product
was mixed with 1-μL ROX and 1-μL loading buffer and
the mixture analyzed with an ABI Prism 373 DNA
Sequencer (Applied Biosystems, Foster City, CA, USA).
To confirm genotyping results, 10 % of representative
PCR products were examined by DNA sequencing in an
ABI Prism 310 Sequence (Applied Biosystems). Results
between PCR-LDR and DNA sequencing analysis were
100 % concordant.
Statistical analyses
Statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, NC, USA). Deviation from
Hardy–Weinberg equilibrium was tested using a χ2 test
for goodness of fit. The genotype and allele frequencies
of the polymorphisms in the patient and control group
were compared using a χ2 test and odds ratios (OR);
95 % confidence intervals (CIs) calculated to assess the
relative risk conferred by a particular allele and geno-
type, adjusted for age and sex. The Benjamini–Hochberg
method was used to determine the false positive discov-
ery rate from multiple testing. Data were further strati-
fied by EBV infection or genotypes to evaluate stratum
variable related ORs. The linkage disequilibrium of the
polymorphic loci and haplotypes were analyzed using
SHEsis software, available from Bio-X Inc., Shanghai,
China). Statistical significance was set at P < 0.05.
Results
Characteristics of NK/T lymphoma patients and controls
The demographic characteristics of cases and controls
are listed in Table 2. There were no statistical differences
in the age and sex distributions between cases and con-
trols. According to the Ann Arbor–Cotswolds staging
system, 63 NK/T-cell lymphoma patients were classified
as stage IE, 38 as stage IIE, 15 as stage IIIE, and 9 as stage
IVE. Approximately 78.4 % (98/125) of all NK/T lymph-
oma cases were nasal cavity and nasopharynx, others
(21.6 %, 27/125) were concentrated in the palate, oro-
pharynx, tonsils, skin, and gastrointestinal tract.
IL-10, TNF, LTA, and CTLA-4 genotypes and haplotypes of
NK/T lymphoma
The genotype and allele frequencies and the respective
controls of the IL-10, TNF/LTA, and CTLA-4 gene regions
in patients with NK/T lymphoma are listed in Table 3. All
Table 1 Genes and single nucleotide polymorphisms (SNPs) that were evaluated
Gene names Description Chromosome location SNP rsID Polymorphism
IL-10 Interleukin-10 1q31-q32 rs1800871 -819C > T
rs1800872 -592C > A
rs1800896 -1082A > G
rs1800890 -3575 T > A
TNF-α Tumor necrosis factor-α 6p21.3 rs1799724 -857C > T
rs1800629 -308G > A
rs361525 -238G > A
LTA Lymphotoxin-alpha 6p21.3 rs909253 252A > G
CTLA4 Cytotoxic T-lymphocyte-associated 4 2q33 rs4553808 -1661A > G
rs5742909 -318C > T
rs231775 +49A > G
rs3087243 CT60A > G
Table 2 Demographic characteristics of patients with NK/T cell





OR (95 % CI) P value
Age, years
Mean 43.0 ± 15.0 44.9 ± 14.8 0.569
Sex
Male 83 198 1
Female 42 102 0.98(0.63-1.53) 0.937
EBV serology test
Negative 47 271 1
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genotype frequencies were in Hardy–Weinberg equilib-
rium. Interestingly, the LTA +252 A >G polymorphism
was significantly associated with the risk of developing
NK/T lymphoma. Compared to common genotypes, the
LTA +252 GA+AA genotype and A allele were associated
with increased risk for NK/T-cell lymphoma (OR = 2.96,
95 % CI = 1.42–6.19, P = 0.004 for the GA +AA genotype;
OR = 1.40, 95 % CI = 1.03–1.89, P = 0.03 for the A allele).
After accounting for multiple comparisons, the LTA +252
GA +AA genotype remained significantly associated with
NK/T-cell lymphoma. However, no statistical significance
was noted in the overall risk of developing NK/T lymph-
oma for IL-10, TNF-α, and CTLA4 genotypes.
Haplotype analyses were performed and the most
common haplotype frequencies are shown in Table 4.
Table 3 Distribution of genotype and allele frequencies in with
NK/T lymphoma patients and controls
Genotypes Controls, n (%) Cases, n (%) OR (95 % CI) P value
IL-10 -3575
TT 278(93) 117(94) 1
TA 22(7) 8(6) 0.86(0.37-1.99) 0.73
AA 0 0
T 578(96) 242(97) 1
A 22(4) 8(3) 0.87(0.38-1.98) 0.73
IL-10 -1082
AA 237(79) 101(81) 1
AG 60(20) 24(19) 0.94(0.55-1.59) 0.81
GG 3(1) 0(0)
A 534(89) 226(90) 1
G 66(11) 24(10) 0.86(0.52-1.41) 0.55
IL-10 -819
CC 39(13) 9(7) 1
CT 125(42) 59(47) 2.00(0.93-4.49) 0.08
TT 136(45) 57(46) 1.81(0.83-3.99) 0.14
C 203(34) 76(30)
T 397(66) 174(70) 1.17(0.85-1.61) 0.33
IL-10 -592
CC 38(13) 9(7) 1
AC 124(41) 59(47) 2.00(0.91-4.43) 0.08
AA 138(46) 57(46) 1.74 (0.79-3.84) 0.17
C 200(33) 77(31) 1
A 400(67) 173(69) 1.12(0.82-1.54) 0.47
TNF-α -857
CC 239(79) 96(78) 1
CT 56(19) 28(22) 1.25(0.75-2.08) 0.40
TT 5(1) 1(0) 0.50(0.06-4.32) 0.53
C 534(89) 220(88) 1
T 66(11) 30(12) 1.10(0.69-1.75) 0.68
TNF-α -308
GG 260(87) 115(92) 1
AG 40(13) 10(8) 0.56 (0.27-1.17) 0.12
AA 0 0
G 560(93) 240(96) 1
A 40(7) 10(4) 0.58 (0.29-1.19) 0.14
TNF-α -238
GG 267(89) 116(93) 1
AG 32(11) 9(7) 0.65(0.30-1.40) 0.27
AA 1(0) 0(0) -
G 566(94) 241(96) 1
A 34(6) 9(4) 0.62(0.29-1.32) 0.21
LTA +252
Table 3 Distribution of genotype and allele frequencies in with
NK/T lymphoma patients and controls (Continued)
GG 56(19) 9(7) 1
GA 149(50) 71(57) 2.95(1.34-6.48) 0.01*
AA 95(31) 45(36) 2.97(1.39-6.33) 0.01*
GA + AA 244(81) 116(93) 2.96(1.42-6.19) 0.004*
G 261(44) 89(36) 1
A 339(56) 161(64) 1.39(1.03-1.89) 0.03*
CTLA-4 -1661
AA 216(72) 84(67) 1
AG 78(26) 40(32) 1.32(0.84-2.08) 0.24
GG 6(2) 1(0) 0.43(0.05-3.61) 0.44
G 90(15) 42(17) 1
A 510(85) 208(83) 0.87(0.59-1.30) 0.51
CTLA-4 -318
CC 222(74) 88(70) 1
CT 73(24) 36(29) 1.24(0.78-1.99) 0.36
TT 5(2) 1(0) 0.51(0.05-4.38) 0.54
C 517(86) 212(85) 1
T 83(14) 38(15) 1.11(0.74-1.69) 0.60
CTLA-4 + 49
AA 34(11) 8(6) 1
GA 118(39) 60(48) 2.16(0.94-4.96) 0.07
GG 148(49) 57(46) 1.64(0.72-3.75) 0.24
A 186(31) 76(30) 1
G 414(69) 174(70) 0.97(0.71-1.34) 0.86
CTLA-4 CT60
AA 10(3) 3(2) 1
GA 82(27) 32(26) 1.30(0.34-5.04) 0.70
GG 208(69) 90(72) 1.44(0.39-5.36) 0.58
A 102(17) 38(15) 1
G 498(83) 212(85) 1.14(0.76-1.71) 0.52
*adjusted for age, sex
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Details of linkage disequilibrium tests (D’) are shown in
Fig. 1. These analyses showed that the most common
haplotype, C-G-G-A of TNF/LTA, had an increased risk
of NK/T lymphoma (OR = 1.52, 95%CI = 1.13 ~ 2.04, P <
0.01), compared to carriers of the non-CGGA haplotype.
No statistical difference was observed between IL-10
and CTLA-4 haplotypes and NK/T-cell lymphomas.
Stratification analysis by EBV infection of IL-10, TNF, LTA,
and CTLA-4 genotypes and NK/T lymphoma
In this study, EBV infection was significantly higher for
cases (62.4 %) than controls (9.7 %). Thus, the relation-
ship between gene polymorphisms and NK/T lymphoma
risk was further analyzed with respect to EBV serology.
Except for the LTA + 252 genotype, no other genotypes
were significantly associated with NK/T lymphoma risk.
However, the LTA +252 GA + AA genotype was associ-
ated with an increased risk of NK/T lymphoma among
EBV-positive populations (OR = 5.20, 95 % CI = 1.22–
23.41, P = 0.03, Table 5). Nevertheless, we found no
evidence of interaction between LTA +252 G > A
polymorphism and EBV serology in relation to NK/T
lymphoma risk (P interaction = 0.397). These data
indicate that the LTA +252 GA + AA genotype likely in-
fluences the inflammatory response to EBV infection,
which may ultimately alter the risk for developing NK/
T lymphoma.
Discussion
The genetic associations between IL-10, TNF/LTA, and
CTLA-4 polymorphisms have been investigated exten-
sively in many autoimmune diseases and malignancies,
and have been confirmed for certain diseases. In lymph-
oma, IL-10 -3575A and TNF -308G increase the risk of
DLBCL [11, 12], and CTLA-4 + 49 A > G increases the
risk of MALT lymphoma [19]. In this study, our results
showed that LTA +252 A > G polymorphism is associ-
ated with a 2.9-fold risk of NK/T-cell lymphoma, but
other polymorphisms of the IL-10, TNF-α, and CTLA-4
genes are not. The most common haplotype, CGGA
(TNF-α-857 C > T, -308 G > A, -238 G > A, LTA +252
A > G) conferred a 1.5-fold risk of NK/T-cell lymphoma.
Furthermore, the LTA +252 GA +AA genotype was as-
sociated with an increased NK/T lymphoma risk among
EBV–positive populations. Thus, our results suggest that
the LTA +252 polymorphism may play an important role
in the NK/T-cell lymphoma development, particularly in
those who are EBV infected.
Table 4 Distribution of haplotype frequencies in NK/T-cell
lymphoma patients and controls
haplotype control NK/T OR(95%CI) P
IL-10 -3575,-1082,-819,-592
TATA 393(66) 173(69) 1
TACC 136(23) 53(21) 0.89(0.62-1.27) 0.52
TGCC 40(7) 16(6) 0.91(0.49-1.67) 0.76
AGCC 22(4) 8(3) 0.83(0.36-1.89) 0.65
TNF-α-857,-308,-238,LTA-252
CGGA 242(40) 127(51) 1.52(1.14-2.06) 0.005
Non-CGGA 358(60) 123(49) 1
CGGG 221(37) 76(31) 1.01(0.72-1.39) 0.99
TGGA 65(11) 28(11) 1.25(0.77-2.04) 0.36
CAGG 38(6) 7(3) 0.54(0.23-1.3) 0.14
CTLA-4 -1661,-318,49,CT60
ACGG 410(68) 170(68) 1
ACAA 99(16) 38(15) 0.93(0.61-1.40) 0.71
GTAG 81(14) 38(15) 1.13(0.74-1.73) 0.57
Fig. 1 D’values for linkage disequilibrium between IL-10, TNF/LTA and CTLA-4 SNPs
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Previous studies have shown that LTA is necessary for
the presence of NK cells in the spleen and LTA-/- mice
have fewer splenic NK cells [20]. LTA signaling may be
involved in the maturation and recruitment of NK cells
and is required for NK cell activation [21]. In contrast,
in NK cell-mediated anti-tumor activity, LTA contributes
to tumor rejection by stimulating the host immune re-
sponse [21]. For NK/T lymphoma, no role for LTA in
NK/T-cell malignant transformation has been reported.
Our study shows that individuals with the LTA +252 A
allele have an increased tendency toward NK/T-cell
lymphoma, suggesting that LTA deregulation caused by
genetic polymorphisms may be affected by NK/T lymph-
oma pathogenesis. In our control group, we note that
the LTA +252A and G allele frequencies were 0.56 and
0.44, respectively, similar to the frequencies in healthy
Koreans (0.54 and 0.46, respectively) [22], but different
from Caucasians of European descent (0.68 and 0.32,
respectively) [9, 12]. This suggests that the LTA +252
A > G polymorphism varies among ethnic groups or
geographical regions, and association of the LTA +252
A > G polymorphism with NK/T-cell lymphoma appears
to vary by ethnicity.
The human LTA gene is located on chromosome
6p23-q12 and is closely linked to TNF-α, from which it
is separated by about 1.2Kb. Our study also shows that
the TNF/LTA haplotype CGGA (TNF-α -857C/-308G/
-238G/LTA +252A) has a 1.5-fold increased risk of NK/
T-cell lymphoma compared with those of non-CGGA
types. The TNF/LTA haplotypes in most studies focused
on the TNF-308 and LTA +252 loci, with significant as-
sociations between high-producer TNF-α- 308A/LTA
+252G haplotypes and increased risk of DLBCL [9]. In
contrast, our results suggest that TNF-α −308 G and
LTA +252 A haplotypes increase the risk of NK/T-cell
lymphoma. The TNF/LTA locus is located within the
major histocompatibility complex (HLA) class III region.
This region has many polymorphisms and regulates the
immune response to infection and malignant trans-
formation. Several studies have described substantial
genetic variations in the HLA-DRB1 and LTA-TNF
regions in Caucasians and Asians [23, 24], which may
lead to different levels of NHL susceptibility. Fine map-
ping and functional studies of SNPs across this region
will be required to determine whether the TNF-α–
308 G > A and LTA +252 A > G SNPs constitute distinct
susceptibility alleles or whether they are linked to other
causal HLA loci.
In this study, EBV infection is commonly observed in
nasal NK/T lymphoma, but its oncogenic mechanism
remains unclear. Some studies have shown that EBV can
be integrated into the host cell genome, causing lympho-
cyte immortalization [25, 26]. In addition, it has been
suggested that EBV stimulates T lymphocytes, releasing
a variety of cytokines such as TNF, interferon (IFN), and
interleukin-1 (IL-1), which may lead to immune dys-
function [27]. Chronic inflammation induced by viral
infection may result in complex interrelated degenera-
tive and regenerative processes, promoting the accumu-
lation of critical mutations in the host genome. This
may be the reason why chronic inflammation is closely
related to a number of cancers. The present study de-
scribes, for the first time, the significantly higher pres-
ence of the LTA +252 G > A genotype in NK/T
lymphoma patients (OR = 2.9, 95 % CI = 1.42–6.19) and
EBV-positive populations (OR = 5.2, 95 % CI = 1.22–
23.41, P = 0.03). This leads us to infer that this allele
combined with H. pylori infection may further increase
the risk for developing NK/T-cell lymphoma.
LTA and TNF-α are key members of the TNF family,
and are similar in gene structure, protein molecular
structure, and biological function. However, they have
many differences with respect to cellular origin and
regulation of gene expression. Our results show that the
LTA, but not the TNF gene, polymorphism serves as a
genetic marker for NK/T-cell lymphoma, which suggests
that subtle genetic differences may be involved in regu-
lating different signaling pathways and leading to differ-
ent pathogenesis among lymphoma subtypes.
Conclusions
Our data suggest that the LTA +252 A > G polymorph-
ism is associated with the risk of developing NK/T-cell
lymphoma in a Chinese population, especially with EBV-
positive NK/T-cell lymphoma.
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